VLVerena Lentsch

Verena Lentsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Verena Lentsch has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phage-steering permits antibody-mediated clearance of E. coli K1 from the gut

    by Louise Larsson, Anouk Bertola, Nicolas Wenner, Jasmine Kaur, Sara Dion, Leonardo Lemos Rocha, Timothy Keys, Christoph Rutschmann, Kateryna Vershynina, Despoina Dimakou, et al.

    Escherichia coli (E. coli) strains expressing the capsule serotype K1 (E. coli K1) are a prevalent cause of neonatal sepsis and meningitis. The gut microbiota of healthy adults is a natural reservoir of E. coli K1, from which it can spread to extra-intestinal sites or be transmitted from mother to infant during birth. Accordingly, shifting gut colonization from potentially pathogenic E. coli strains to more benign strains could reduce the risk of disease. Here, we leverage selective pressures exerted by bacteriophage and mucosal antibodies to limit gut colonization by E. coli K1 and prevent its transmission. K1-specific bacteriophages (phages) rapidly drive a within-host evolution of capsule-less mutants with exposed surface O-antigens. These mutants become susceptible to vaccine-induced intestinal IgA targeting the bacterial O-antigen, allowing competitive exclusion by the probiotic strain E. coli Nissle. In a murine vertical transmission model, 77% of pups were protected from transmission of E. coli K1 when the mother was vaccinated and treated with phages, whereas E. coli K1 was detected in most pups by day 10 of life when the mother received vaccination or phage therapy alone. Although the high diversity of E. coli makes generalization challenging, combining vaccination with phage-steering represents a promising approach for further exploration in eliminating infectious reservoirs.


  • Open Access

    Author Correction: Spatial fibroblast niches define Crohn’s fistulae

    by Colleen McGregor, Xiao Qin, Marta Jagielowicz, Tarun Gupta, Zinan Yin, Verena Lentsch, David Fawkner-Corbett, Vy Wien Lai, Paula Gomez Castro, Esther Bridges, et al.


  • Open Access

    Spatial fibroblast niches define Crohn’s fistulae

    by Colleen McGregor, Xiao Qin, Marta Jagielowicz, Tarun Gupta, Zinan Yin, Verena Lentsch, David Fawkner-Corbett, Vy Wien Lai, Paula Gomez Castro, Esther Bridges, et al.

    Crohn’s disease often presents with fistulae, abnormal tunnels that connect the intestine to the skin or other organs. Despite their profound effect on morbidity, the molecular basis of fistula formation remains unclear, largely owing to the challenge of capturing intact fistula tracts and their inherent heterogeneity 1–3 . Here we construct a subcellular-resolution spatial atlas of 68 intestinal fistulae spanning diverse anatomical locations. We describe fistula-associated epithelial, immune and stromal cell states, revealing abnormal zonation of growth factors and morphogens linked to establishment of tunnelling anatomy. We identify fistula-associated stromal (FAS) fibroblasts, which are assembled in concentric layers: a proliferative, lumen-adjacent zone beneath neutrophil and macrophage-rich granulation tissue, an active lesion core of FAS cells and a quiescent, pro-fibrotic outer zone. We examine the architecture of the extracellular matrix in the fistula tract and demonstrate that FAS populations associate with distinct collagen structures, exhibiting properties ranging from proliferation, migration and extracellular matrix remodelling to dense collagen deposition and fibrosis. We define niches supporting epithelialization of fistula tunnels and a FAS-like population that is detected at the base of ulcers in non-penetrating Crohn’s disease. Our study demonstrates that common molecular pathways and cellular niches underpin fistulae across intestinal locations, revealing the cellular protagonists of fistula establishment and persistence. This resource will inform the development of model systems and interventions to mitigate aberrant fibroblast activity while preserving their regenerative properties in Crohn’s disease.


  • Vaccine-enhanced competition permits rational bacterial strain replacement in the gut

    by Verena Lentsch, Aurore Woller, Andrea Rocker, Selma Aslani, Claudia Moresi, Niina Ruoho, Louise Larsson, Stefan A. Fattinger, Nicolas Wenner, Elisa Cappio Barazzone, et al.

    Colonization of the intestinal lumen precedes invasive infection for a wide range of enteropathogenic and opportunistic pathogenic bacteria. We show that combining oral vaccination with engineered or selected niche-competitor strains permits pathogen exclusion and strain replacement in the mouse gut lumen. This approach can be applied either prophylactically to prevent invasion of nontyphoidal Salmonella strains, or therapeutically to displace an established Escherichia coli. Both intact adaptive immunity and metabolic niche competition are necessary for efficient vaccine-enhanced competition. Our findings imply that mucosal antibodies have evolved to work in the context of gut microbial ecology by influencing the outcome of competition. This has broad implications for the elimination of pathogenic and antibiotic-resistant bacterial reservoirs and for rational microbiota engineering.


  • Open Access

    Surface crosslinking of virus-like particles increases resistance to proteases, low pH, and mechanical stress for mucosal applications

    by Ahmed Ali, Suwannee Ganguillet, Yagmur Turgay, Tim Keys, Erika Causa, Ricardo Fradique, Viviane Lutz-Bueno, Serge Chesnov, Chia-Wei Lin, Verena Lentsch, et al.

    Virus-like particles (VLPs) are emerging as nano-scaffolds in a variety of biomedical applications including the delivery of vaccine antigens and therapeutic molecules. These soft, colloidal, and proteinaceous structures are nevertheless susceptible to environmental factors such as mechanical stress, proteases and low pH which limit their usefulness, particularly for mucosal applications. We addressed this issue by crosslinking multiple surface sites using polyethylene glycol linkers. Surface crosslinking enhanced the colloidal stability and mechanical strength of VLPs against pH, proteases, and mechanical stresses. Chemical crosslinking thus offers a viable means to enhance resilience of VLPs in mucosal applications. Teaser Polyethylene glycol crosslinking virus-like particle (VLP) capsids enhanced the stability and strength of VLPs in mucosal environments.


  • Open Access

    “EvoVax” – A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs

    by Verena Lentsch, Selma Aslani, Thomas Echtermann, Swapan Preet, Elisa Cappio Barazzone, Daniel Hoces, Claudia Moresi, Dolf Kümmerlen, Emma Slack


  • Open Access

    A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs

    by Verena Lentsch, Selma Aslani, Thomas Echtermann, Swapan Preet, Elisa Cappio Barazzone, Daniel Hoces, Claudia Moresi, Dolf Kuemmerlen, Emma Slack

    Salmonella enterica subspecies enterica serovar Typhimurium ( S .Tm) poses a considerable threat to public health due to its zoonotic potential. Human infections are mostly foodborne, and pork and pork products are ranked among the top culprits for transmission. In addition, the high percentage of antibiotic resistance, especially in monophasic S .Tm, limits treatment options when needed. Better S .Tm control would therefore be of benefit both for farm animals and for safety of the human food chain. A promising pre-harvest intervention is vaccination. In this study we tested safety and immunogenicity of an oral inactivated S .Tm vaccine, which has been recently shown to generate an “evolutionary trap” and to massively reduce S .Tm colonization and transmission in mice. We show that this vaccine is highly immunogenic and safe in post-weaning pigs and that administration of a single oral dose results in a strong and long-lasting serum IgG response. This has several advantages over existing – mainly live – vaccines against S .Tm, both in improved seroconversion and reduced risk of vaccine-strain persistence and reversion to virulence.

  • Open Access

    Vaccine-enhanced competition permits rational bacterial strain replacement in the gut

    by Verena Lentsch, Aurore Woller, Andrea Rocker, Selma Aslani, Claudia Moresi, Niina Ruoho, Louise Larsson, Stefan A. Fattinger, Nicolas Wenner, Elisa Cappio Barazzone, et al.

    Widespread antimicrobial resistance generates an urgent need to develop better disease prophylaxis for intestinal bacterial pathogens. While the first phase of infection with any bacterial pathogen is typically colonization of the mucosal surfaces, current vaccine strategies typically target invasive stages of disease. Here we demonstrate the ability to specifically generate sterilizing immunity against Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm) at the level of gut lumen colonization using a combination of oral vaccination and a rationally-designed niche competitor strain. This is based on the proven ability of specific secretory IgA to generate a fitness disadvantage for a targeted bacterium, allowing a non-targeted competitor to rapidly overtake its niche. By hugely decreasing the population size of an intestinal pathogen during the early stages of infection, this improves protection of gut tissue compared to standard licensed animal vaccines. We demonstrate that most effective protection is generated when the niche competitor is derived from the pathogen and therefore occupies an identical niche. However, as this is unrealistic in real-world infections, we further demonstrate that robust protection can also be generated with a more distantly related “probiotic” niche competitor from a distinct species. Interestingly, focusing prophylaxis on the gut lumen reveals an uncoupling of protective mechanisms required for protection in the gut and gut tissues and those required for protecting against colonization of the spleen and liver. Therefore, while there is still potential to improve this approach by adding systemic immune activation, we nevertheless believe this is a fundamental step forward in our ability to manipulate colonization of intestinal bacteria with potential application to a wide-range of entero-pathogens, as well as to manipulation of microbiota composition.


  • A rationally designed oral vaccine induces immunoglobulin A in the murine gut that directs the evolution of attenuated Salmonella variants

    by Médéric Diard, Erik Bakkeren, Verena Lentsch, Andrea Rocker, Nahimi Amare Bekele, Daniel Hoces, Selma Aslani, Markus Arnoldini, Flurina Böhi, Kathrin Schumann-Moor, et al.

    The ability of gut bacterial pathogens to escape immunity by antigenic variation—particularly via changes to surface-exposed antigens—is a major barrier to immune clearance1. However, not all variants are equally fit in all environments2,3. It should therefore be possible to exploit such immune escape mechanisms to direct an evolutionary trade-off. Here, we demonstrate this phenomenon using Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm). A dominant surface antigen of S.Tm is its O-antigen: a long, repetitive glycan that can be rapidly varied by mutations in biosynthetic pathways or by phase variation4,5. We quantified the selective advantage of O-antigen variants in the presence and absence of O-antigen-specific immunoglobulin A and identified a set of evolutionary trajectories allowing immune escape without an associated fitness cost in naive mice. Through the use of rationally designed oral vaccines, we induced immunoglobulin A responses blocking all of these trajectories. This selected for Salmonella mutants carrying deletions of the O-antigen polymerase gene wzyB. Due to their short O-antigen, these evolved mutants were more susceptible to environmental stressors (detergents or complement) and predation (bacteriophages) and were impaired in gut colonization and virulence in mice. Therefore, a rationally induced cocktail of intestinal antibodies can direct an evolutionary trade-off in S.Tm. This lays the foundations for the exploration of mucosal vaccines capable of setting evolutionary traps as a prophylactic strategy.


  • Open Access

    How the Gut Microbiota Influences Our Health and How We Can Influence It

    by Markus Arnoldini, Verena Lentsch, Daniela Latorre, Giorgia Greter, Emma Slack, Ambra Giorgetti, Alessandro Groppo, Lilian Kha

    The microbes in the human gut, also known as the gut microbiota, are known to play a part in how we feel and whether we are healthy or sick. How the microbiota regulates health is still unknown in most cases, and medical treatments to manipulate the microbiota to improve people’s health are only just starting to be used. In this article, we explain how the gut microbiota is currently studied, what we already understand about how the gut microbiota influences health, and ways that are already used, or are being investigated, to influence the microbiota to improve health.